Gross Profit Comparison: Teva Pharmaceutical Industries Limited and Evotec SE Trends

Teva vs. Evotec: A Decade of Diverging Profits

__timestampEvotec SETeva Pharmaceutical Industries Limited
Wednesday, January 1, 20142937800011056000000
Thursday, January 1, 20153798700011356000000
Friday, January 1, 20165855400011859000000
Sunday, January 1, 20178256800010825000000
Monday, January 1, 20181120160008296000000
Tuesday, January 1, 20191328910007536000000
Wednesday, January 1, 20201257430007725000000
Friday, January 1, 20211515430007594000000
Saturday, January 1, 20221740650006973000000
Sunday, January 1, 20231750510007646000000
Monday, January 1, 20248064000000
Loading chart...

Unlocking the unknown

A Tale of Two Pharmaceutical Giants: Teva and Evotec

In the ever-evolving pharmaceutical industry, the financial health of companies is a key indicator of their market position and potential for innovation. Over the past decade, Teva Pharmaceutical Industries Limited and Evotec SE have showcased contrasting trends in their gross profit margins. From 2014 to 2023, Teva's gross profit has seen a decline of approximately 31%, reflecting challenges in the competitive landscape and pricing pressures. In contrast, Evotec SE has experienced a remarkable growth of nearly 500% in the same period, highlighting its strategic advancements and successful partnerships.

This data underscores the dynamic nature of the pharmaceutical sector, where adaptability and strategic foresight are crucial. As Teva navigates its challenges, Evotec's upward trajectory serves as a testament to the power of innovation and collaboration in driving financial success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025